As of February 10, 2026, Biosig Technologies Inc has a Discounted Cash Flow (DCF) derived fair value of $0.00 per share. With the current market price at $6.10, this represents a potential upside of -289.4%.
| Key Metrics | Value |
|---|---|
| DCF Fair Value (5-year) | $0.00 |
| DCF Fair Value (10-year) | $0.00 |
| Potential Upside (5-year) | -292.1% |
| Potential Upside (10-year) | -289.4% |
| Discount Rate (WACC) | 5.2% - 6.4% |
| Fiscal Year | Revenue (USD millions) | Growth |
|---|---|---|
| 12-2024 | 0 | 122% |
| 12-2025 | 0 | 5% |
| 12-2026 | 0 | 3% |
| 12-2027 | 0 | 4% |
| 12-2028 | 0 | 5% |
| 12-2029 | 0 | 2% |
| 12-2030 | 0 | 4% |
| 12-2031 | 0 | 5% |
| 12-2032 | 0 | 2% |
| 12-2033 | 0 | 5% |
| 12-2034 | 0 | 2% |
Net profit margin is expected to improve from -25000% in 12-2024 to -1049% by 12-2034, driven by operational efficiency and economies of scale.
| Fiscal Year | Net Profit (USD millions) | Profit Margin |
|---|---|---|
| 12-2024 | (10) | -25000% |
| 12-2025 | (8) | -770% |
| 12-2026 | (8) | -795% |
| 12-2027 | (8) | -824% |
| 12-2028 | (9) | -862% |
| 12-2029 | (9) | -879% |
| 12-2030 | (9) | -910% |
| 12-2031 | (10) | -959% |
| 12-2032 | (10) | -979% |
| 12-2033 | (10) | -1028% |
| 12-2034 | (10) | -1049% |
with a 5-year average of $0 million. Projected CapEx is expected to maintain at approximately 405% of revenue.
Depreciation is based on an average useful life of 5 years for capital assets.
| Fiscal Year | D&A (USD millions) |
|---|---|
| 12-2025 | 0 |
| 12-2026 | 0 |
| 12-2027 | 0 |
| 12-2028 | 0 |
| 12-2029 | 0 |
| 12-2030 | 0 |
Net working capital is expected to increase gradually, with projected changes affecting free cash flow.
| Components | Average Days |
|---|---|
| Days Receivables | 166 |
| Days Inventory | 717 |
| Days Payables | 0 |
| Fiscal Year | EBITDA | Tax | CapEx | Change in NWC | FCF |
|---|---|---|---|---|---|
| 6M/2025 | (5) | (1) | 0 | 0 | (4) |
| 2026 | (11) | (3) | 0 | 0 | (8) |
| 2027 | (11) | (3) | 0 | (0) | (8) |
| 2028 | (12) | (3) | 0 | 0 | (9) |
| 2029 | (12) | (3) | 0 | 0 | (9) |
| Valuation Method | Fair Price (USD) | Potential Upside |
|---|---|---|
| 5-Year DCF (Growth) | 0.00 | -292.1% |
| 10-Year DCF (Growth) | 0.00 | -289.4% |
| 5-Year DCF (EBITDA) | 0.00 | -100.0% |
| 10-Year DCF (EBITDA) | 0.00 | -100.0% |
Is Biosig Technologies Inc (BSGM) a buy or a sell? Biosig Technologies Inc is definitely a sell. Based on our DCF analysis, Biosig Technologies Inc (BSGM) appears to be overvalued with upside potential of -289.4%. The company's strong projected growth in revenue and profitability, coupled with consistent capital expenditure, supports our positive outlook on its intrinsic value.
Key investment drivers include:
Investors should consider reducing exposure at the current market price of $6.10.